



## BioPharmica Limited

29 June 2007

BioPharmica [ASX: BPH] ASX Release

### **BIOPHARMICA TO MOVE TO 83.5% IN HLS5 INVESTMENT**

BioPharmica has entered into an agreement with the University of Western Australia and the Western Australian Institute for Medical research to increase its interest in the HLS5 Project to 83.5%.

BioPharmica will now provide the further funding to the project to now earn this interest.

The provision of this funding by BioPharmica will be used to further integrate the research project with the innovative skills and technology available to BioPharmica through its wholly owned subsidiary Molecular Discovery Systems.

MDS is identifying patterns/features/markers found in tissue and cellular samples and is incorporating these into tissue array and cell based assay imaging tools to be used in target validation, drug screening, biomarker validation, diagnostics and for potential use in pathology.

The HLS5 Project is seeking to commercialise patents it has filed relating to the HLS5 gene as a target for diagnostic, prognostic or therapeutic use.

Under the terms of this Agreement, MDS is to conduct a range of Tasks for the HLS5 Project in order to assist it to validate HLS5 as a cancer target.

As consideration for MDS conducting the agreed tasks, the HLS5 Project will provide MDS with a world wide exclusive license to commercialize HLS5 in the field of cell based imaging.

### **About BioPharmica Limited**

BioPharmica [ASX: BPH] is an Australian Stock Exchange listed company developing biomedical research with academic and hospital institutes. The Company provides early stage funding for a direct collaboration, a spin out company or to secure a license. BioPharmica provides assistance with product development, funding and commercial strategies, whilst the institutional partner provides a majority of the infrastructure and research expertise.

**MORE INFORMATION: Jenny Tollet, Commercialization Manager, Tel +61 8 9328 8366.**

Yours faithfully

David Breeze  
Chairman

### **BioPharmica Limited**

ACN 95 912 002

PO Box 317, North Perth Western Australia 6906

14 View Street, North Perth Western Australia 6006

admin@biopharmica.com.au www.biopharmica.com.au

T: +61 8 9328 8366 F: +61 8 9328 8733